HLA-B*57与IFNL4相关多态性对HIV-1控制者疾病进展的保护作用
本研究在西班牙队列(n=140)和国际验证队列(n=914)中分析HIV-1控制者,发现HLA-B*57与长期不进展表型独立相关,而IFNL4相关基因型是非长期不进展的独立因素,且长期不进展者具有较低的IP-10和较高的IFN-γ水平及特定HIV-1特异性CD8+T细胞。
要点
- HLA-B*57与HIV-1控制者长期维持CD4>500 cells/mm3独立相关。
- IFNL4相关基因型(TT/TT或A/A)是非长期不进展的独立因素。
- 长期不进展者IP-10较低、IFN-γ较高,且特定CD8+T细胞数量较高。
核心结论
- HLA-B*57和IFNL4相关多态性可区分稳定HIV-1控制者与将发生CD4+T细胞下降者。
研究设计与样本
- 研究纳入西班牙队列(n=140)和国际验证队列(n=914),比较长期不进展HIV-1控制者(LTNP-C)与非LTNP-C。
主要发现
- HLA-B*57与LTNP-C表型独立相关(西班牙队列OR=3.056 (1.029-9.069) p=0.044;验证队列OR=1.924 (1.252-2.957) p=0.003)。
- IFNL4基因型TT/TT(ss469415590)与非LTNP-C独立相关(OR=0.401 (0.171-0.942) p=0.036)。
- IFNL4基因型A/A(rs12980275)与非LTNP-C独立相关(OR=0.637 (0.434-0.934) p=0.021)。
- LTNP-C血浆IP-10较低(p=0.019)、IFN-γ较高(p=0.02)。
- LTNP-C的IL2+CD57-和IFN-γ+CD57- HIV-1特异性CD8+T细胞数量较高(p=0.002和0.041)。
关键数值与推荐
- LTNP-C定义为HIV-1诊断后维持CD4+T细胞计数>500 cells/mm3超过7年。
- 非LTNP-C为CD4+T细胞计数降至<500 cells/mm3者。
临床怎么用
- 检测HLA-B*57和IFNL4相关多态性有助于识别有免疫进展风险的HIV-1控制者。
- 上述标志物可为个体化治疗干预和精准医疗提供依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HIV-1-controllers maintain HIV-1 viremia at low levels (normally <2000 HIV-RNA copies/mL) without antiretroviral treatment. However, some HIV-1-controllers have evidence of immunologic progression with marked CD4+T-cell decline. We investigated host genetic factors associated with protection against CD4+T-cell loss in HIV-1-controllers. METHODS: We analysed the association of interferon lambda 4 (IFNL4)-related polymorphisms and HLA-B haplotypes within Long Term Non-Progressor HIV-1-controllers ((LTNP-C), defined by maintaining CD4+T-cells counts >500 cells/mm3 for more than 7 years after HIV-1 diagnosis) versus non-LTNP-C, who developed CD4+T-cells counts <500 cells/mm3 Both a Spanish study cohort (n=140) and an international validation cohort (n=914) were examined. Additionally, in a subgroup of individuals HIV-1-specific T-cell responses and soluble cytokines were analysed RESULTS: HLA-B*57 was independently associated with the LTNP-C phenotype (OR=3.056 (1.029-9.069) p=0.044 and OR=1.924 (1.252-2.957) p=0.003) while IFNL4 genotypes represented independent factors for becoming non-LTNP-C (TT/TT, ss469415590, OR=0.401 (0.171-0.942) p=0.036 or A/A, rs12980275, OR=0.637 (0.434-0.934) p=0.021) in the Spanish and validation cohort, respectively, after adjusting for sex, age at HIV-1 diagnosis, IFNL4-related polymorphisms and different HLA-B haplotypes. LTNP-C showed lower plasma IP-10 (p=0.019) and higher IFN-γ (p=0.02) levels than the HIV-1-controllers with diminished CD4+T-cell numbers. Moreover, LTNP-C exhibited higher quantities of IL2+CD57- and IFN-γ+CD57- HIV-1-specific CD8+T-cells (p=0.002 and 0.041, respectively) than non-LTNP-C. CONCLUSIONS: We have defined genetic markers able to segregate stable HIV-1-controllers from those who experience CD4+T-cell decline. These findings allow for identification of HIV-1-controllers at risk for immunologic progression, and provide avenues for personalized therapeutic interventions and precision medicine for optimizing clinical care of these individuals.
引用
- Dominguez-Molina B, Tarancon-Diez L, Hua S, et al. HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers. Clin Infect Dis. 2016. PMID: 27986689
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。